Tetralogic Pharmaceuticals Corp Coverage Initiated at Oppenheimer (TLOG)
Stock analysts at Oppenheimer began coverage on shares of Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) in a report issued on Monday, Analyst Ratings Network reports. The firm set an “outperform” rating on the stock.
Other equities research analysts have also recently issued reports about the stock. Analysts at Needham & Company initiated coverage on shares of Tetralogic Pharmaceuticals Corp in a research note to investors on Monday. They set a “buy” rating on the stock. Analysts at Guggenheim initiated coverage on shares of Tetralogic Pharmaceuticals Corp in a research note to investors on Monday. They set a “buy” rating and a $15.00 price target on the stock.
Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) traded up 2.00% during mid-day trading on Monday, hitting $10.6899. 77,016 shares of the company’s stock traded hands. Tetralogic Pharmaceuticals Corp has a 1-year low of $6.91 and a 1-year high of $10.97. The stock has a 50-day moving average of $8.1 and a 200-day moving average of $8.1. The company’s market cap is $137.8 million.
TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) is a clinical-stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.